The Wall Street Journal (8/12, Loftus, Subscription Publication) reports Intercept Pharmaceuticals Inc. disclosed its medication, obeticholic acid, has been found to be effective in mid-stage studies for the treatment of liver disease due to fat accumulation.
Reuters (8/12) reports the company disclosed 46% of patients receiving the experimental medication met the trial’s goal of improvement in liver health, compared with 21 percent in the placebo group.
No comments:
Post a Comment